The digital therapeutics company Progentec Diagnostics announced the new PROACTIVE study—in collaboration with pharmaceutical company GSK—to virtually screen and identify individuals who may be at risk of developing lupus, according to a release from Cision PR Newswire. In the new study, Progentec Diagnostics hopes to provide participants with individualized and comprehensive diagnostics by utilizing advanced biomarker tests, online assessments, and virtual consultations with rheumatologists. Experts stressed that patients who are diagnosed and treated early may respond better to therapies and may be able to manage their symptoms more effectively. “We believe that this study will not only contribute substantially to our understanding of lupus during its early stages, but also provide much needed answers [for patients] who experience unexplained symptoms attributable to lupus,” concluded Eldon Jupe, PhD, Director of the High Complexity Clinical Laboratory at Progentec Diagnostics.
May 25, 2023